Definium Therapeutics Teases 3 Phase III DT120 Readouts in 2026, Starting Late Q2 MDD Data [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
The MDD EMERGE study is a 1:1 randomized, double-blind, placebo-controlled 12-week trial with a 6-week primary MADRS endpoint and is ~80% powered to detect a 5-point placebo-adjusted difference; GAD Phase III trials use a virtually identical design (VOYAGE targets N˜200) and Phase II showed a 7.7-point HAM-A placebo-adjusted benefit at the 100 µg dose. Definium is preparing a clinic-based commercial model with reimbursement pathways and “white glove” site support, and is engaging the FDA on safety/REMS discussions while aiming to demonstrate single-dose durability and practical retreatment schedules. Interested in Definium Therapeutics, Inc.? Here are five stocks we like better. Definium Therapeutics (NASDAQ:DFTX) is approaching what Chief Executive Officer Rob Barrow described as an “incredibly exciting time,” with pivotal data expected this year for DT120, the company's proprietary form of LSD being studied in generalized anxiety disorder (GAD) and major depressive disorder (
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? [Yahoo! Finance]Yahoo! Finance
- Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones [Seeking Alpha]Seeking Alpha
- Definium Therapeutics (DFTX) was given a new $30.00 price target by Stifel Nicolaus.MarketBeat
- Definium Therapeutics (DFTX) was given a new $38.00 price target by Canaccord Genuity Group Inc..MarketBeat
- Definium Therapeutics (DFTX) is now covered by Piper Sandler. They set an "overweight" rating and a $49.00 price target on the stock.MarketBeat
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- DFTX's page on the SEC website